Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0B8WN
|
|||
| Former ID |
DAP000340
|
|||
| Drug Name |
Ranitidine
|
|||
| Synonyms |
Achedos; Acidex; Alquen; Atural; Axoban; Biotidin; Coralen; Curan; Duractin; Ezopta; Fendibina; Gastrial; Gastridina; Gastrolav; Gastrosedol; Istomar; Kuracid; Logast; Mauran; Melfax; Microtid; Noctone; Ptinolin; Quantor; Quicran; RND; Radinat; Randin; Raniben; Raniberl; Ranibloc; Ranidine; Ranifur; Ranin; Raniogas; Raniplex; Ranisen; Raniter; Ranitidin; Ranitidina; Ranitidinum; Ranitiget; Ranitin; Rantacid; Rantidine; Ratic; Raticina; Sampep; Sostril; Taural; Terposen; Ulceranin; Ulcex; Ultidine; Urantac; Verlost; Vesyca; Vizerul; Weichilin; Weidos; Xanidine; ZANTAC; Zantab; Zantadin; Zantic; Ranitidine HCL; Rantidine HCL; Nu-Ranit; Rani-Q; Rani-nerton; Ranitidina [INN-Spanish]; Ranitidine (TN); Ranitidinum [INN-Latin]; Ul-Pep; Zantac (TN); Ranitidine (USAN/INN); Ranitidine [USAN:BAN:INN]; N-(2-((5-((Dimethylamino)methyl)furfuryl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; N (2-(((5-((Dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; (E)-1-N'-[2-[[5-(dimethylaminomethyl)furan-2-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({5-[(dimethylamino)methyl]-2-furyl}methyl)sulfanyl]ethyl}-N'-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({5-[(dimethylamino)methyl]furan-2-yl}methyl)sulfanyl]ethyl}-N'-methyl-2-nitroethene-1,1-diamine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Peptic ulcer [ICD-11: DA61] | Approved | [1], [2] | |
| Therapeutic Class |
Antiulcer Agents
|
|||
| Company |
GlaxoSmithKline
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C13H22N4O3S
|
|||
| Canonical SMILES |
CNC(=C[N+](=O)[O-])NCCSCC1=CC=C(O1)CN(C)C
|
|||
| InChI |
1S/C13H22N4O3S/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3/h4-5,9,14-15H,6-8,10H2,1-3H3/b13-9+
|
|||
| InChIKey |
VMXUWOKSQNHOCA-UKTHLTGXSA-N
|
|||
| CAS Number |
CAS 82530-72-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
615112, 7847488, 7980484, 8149747, 10036397, 10532147, 11111714, 11111715, 11113371, 14776753, 26612202, 26680173, 26748519, 26748520, 26753732, 34666962, 46505543, 47216723, 47515261, 47810695, 48184944, 49846707, 49968693, 50100822, 50107423, 50107424, 50139267, 50286426, 53790194, 57410138, 85209253, 85245763, 90341455, 92124471, 92307665, 92711914, 93166337, 99301528, 103091649, 103155999, 103173566, 104171226, 111610678, 117377112, 117814891, 118258804, 124551883, 124636867, 124881290, 124881291
|
|||
| ChEBI ID |
CHEBI:8776
|
|||
| ADReCS Drug ID | BADD_D01913 ; BADD_D01914 | |||
| SuperDrug ATC ID |
A02BA02
|
|||
| SuperDrug CAS ID |
cas=066357355
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides fragilis HMW 610
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Ranitidine can be metabolized by Bacteroides fragilis HMW 610 (log2FC = -0.442; p = 0.014). | |||
|
Studied Microbe: Bacteroides fragilis HMW 615
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Ranitidine can be metabolized by Bacteroides fragilis HMW 615 (log2FC = -0.493; p = 0.029). | |||
|
Studied Microbe: Bacteroides fragilis str. 3986 T(B)9
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Ranitidine can be metabolized by Bacteroides fragilis str. 3986 T(B)9 (log2FC = -0.349; p = 0.023). | |||
|
Studied Microbe: Bacteroides fragilis str. DS-208
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Ranitidine can be metabolized by Bacteroides fragilis str. DS-208 (log2FC = -0.452; p = 0.021). | |||
|
Studied Microbe: Parabacteroides johnsonii DSM 18315
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Ranitidine can be metabolized by Parabacteroides johnsonii DSM 18315 (log2FC = -0.419; p = 0.022). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
|
Studied Microbe: Bifidobacterium breve DSM 20213
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Ranitidine can be metabolized by Bifidobacterium breve DSM 20213 (log2FC = -0.878; p = 0.005). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Clostridium hathewayi DSM 13479
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Ranitidine can be metabolized by Clostridium hathewayi DSM 13479 (log2FC = -0.443; p = 0.006). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Fusobacteriales | ||||
|
Studied Microbe: Fusobacterium nucleatum subsp. nucleatum ATCC 25586
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Description | Ranitidine can be metabolized by Fusobacterium nucleatum subsp. nucleatum ATCC 25586. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Lactobacillales | ||||
|
Studied Microbe: Enterococcus faecalis V583
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Ranitidine can be metabolized by Enterococcus faecalis V583 (log2FC = -0.498; p = 0.006). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
| Studied Microbe: Gut microbiota unspecific | [5], [6] | |||
| Metabolic Reaction | N-oxide reduction | |||
| Resulting Metabolite | Hydroxyiminoranitidine | |||
| Metabolic Effect | Decrease activity | |||
| Description | Ranitidine can be metabolized to Hydroxyiminoranitidine by gut microbiota through N-oxide reduction, which results in the decrease of the drug's activity. | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Histamine H2 receptor (H2R) | Target Info | Antagonist | [7], [8], [9] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Gastric acid secretion | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Histamine H2 receptor mediated signaling pathway | ||||
| Pathwhiz Pathway | Intracellular Signalling Through Histamine H2 Receptor and Histamine | |||
| Gastric Acid Production | ||||
| Reactome | Histamine receptors | |||
| G alpha (s) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Secretion of Hydrochloric Acid in Parietal Cells | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1234). | |||
| REF 2 | Clinical review of histamine2 receptor antagonists. Arch Intern Med. 1990 Apr;150(4):745-51. | |||
| REF 3 | Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467. | |||
| REF 4 | Bioaccumulation of therapeutic drugs by human gut bacteria. Nature. 2021 Sep;597(7877):533-538. | |||
| REF 5 | Cometabolism of microbes and host: implications for drug metabolism and drug-induced toxicity. Clin Pharmacol Ther. 2013 Nov;94(5):574-81. | |||
| REF 6 | Human gut microbiota plays a role in the metabolism of drugs. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016 Sep;160(3):317-26. | |||
| REF 7 | Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51. | |||
| REF 8 | Hemodynamic significance of histamine synthesis and histamine H1- and H2-receptor gene expression during endotoxemia. Naunyn Schmiedebergs Arch Pharmacol. 2002 Dec;366(6):513-21. | |||
| REF 9 | Effect of the H2 histamine receptor antagonist on oxygen metabolism in some morphotic blood elements in patients with ulcer disease. Hepatogastroenterology. 1998 Jan-Feb;45(19):276-80. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.